Treatment of cancer with dihydropyrazino-pyrazines
US-9505764-B2 · Nov 29, 2016 · US
Treatment of cancer with dihydropyrazino-pyrazines
US10183019B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10183019-B2 |
| Application number | US-201715459111-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2017 |
| Priority date | Apr 17, 2013 |
| Publication date | Jan 22, 2019 |
| Grant date | Jan 22, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for achieving a Response Assessment for Neuro-Oncology (RANO) Working Group for glioblastoma multiforme of complete response, partial response or stable disease in a patient having glioblastoma multiforme characterized by MGMT protein expression or promoter hypomethylation status, comprising administering an effective amount of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof to said patient. 2. The method of claim 1 , wherein the glioblastoma multiforme is that in which the PI3K/mTOR pathway is activated. 3. The method of claim 2 , wherein the glioblastoma multiforme is that in which the PI3K/mTOR pathway is activated due to ERBB2 mutation, PTEN mutation or loss, NF1 mutation or loss, PIK3Ca mutation, EGFR mutation or overexpression, Met amplification, PDGFRa activation or amplification, AKT amplification or a combination thereof. 4. The method of claim 1 , wherein the glioblastoma multiforme is characterized by MGMT protein expression. 5. The method of claim 1 , wherein the glioblastoma multiforme is characterized by MGMT promoter hypomethylation.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the nervous system · CPC title
- A61K31/4985Primary
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10183019B2 cover?
- Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expre…
- Who is the assignee on this patent?
- Signal Pharm Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4985. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).